Epithalamin vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epithalamin
Epithalamin is a natural peptide extract from the pineal gland. It is the precursor compound from which the synthetic Epitalon was derived. Known for anti-aging and telomerase-activating properties.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | Epithalamin | Survodutide |
|---|---|---|
| Mechanism | Similar to Epitalon, it stimulates telomerase production and may help maintain telomere length. Also regulates melatonin synthesis and circadian rhythms. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Research dosing: 10-20mg daily for 10-20 day cycles. Often administered 1-3 times per year in long-term protocols. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Intramuscular or subcutaneous injection. Natural extract may have more variable composition than synthetic Epitalon. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Generally well-tolerated. May affect sleep patterns. Less characterized than synthetic Epitalon. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to Epithalamin:
Unique to Survodutide:
Detailed Analysis
Commonalities
Epithalamin and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Epithalamin for Sleep Quality. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?